Xenetic Biosciences, Inc.
Price Action
Technical Summary
CONSOLIDATINGXenetic Biosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 58), indicating performance broadly in line with the market. Earnings growth of 66% provides fundamental context to the price action. Investors should exercise caution due to high volatility (87% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.10 | -4.86% | BELOW |
| 50 SMA | $3.09 | -4.82% | BELOW |
| 100 SMA | $2.87 | +2.44% | ABOVE |
| 150 SMA | $2.70 | +9.26% | ABOVE |
| 200 SMA | $2.94 | +0.01% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is XBIO in an uptrend right now?
XBIO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is XBIO overbought or oversold?
XBIO's RSI (14) is 41. The stock is in neutral territory, neither overbought nor oversold.
Is XBIO outperforming the market?
XBIO has a Relative Strength (RS) Rating of 58 out of 99. XBIO is performing about average compared to the market.
Where is XBIO in its 52-week range?
XBIO is trading at $2.94, which is 21% of its 52-week high ($13.93) and 9% above its 52-week low ($1.91).
How volatile is XBIO?
XBIO has a Beta of 1.48 and 52-week volatility of 87%. It's more volatile than the S&P 500 - expect bigger swings.